The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Travel Stocks Suffer As UK Extends Quarantine

Fri, 14th Aug 2020 12:12

(Alliance News) - Stocks in London were shaky at midday on Friday as poor economic data from China fostered worry that it economic recovery is faltering, while travel stocks dived after the UK imposed a quarantine on people entering from France, forcing holidaymakers to rush back home to beat the weekend deadline.

In London, the blue-chip FTSE 100 index was down 131.11 points, or 2.1%, at 6,054.80 at midday. The mid-cap FTSE 250 index was off 231.02 points, or 1.3%, at 17,693.48. The AIM All-Share index was down 5.32 points, or 0.6%, at 951.48.

The Cboe UK 100 index was down 2.3% at 603.69. The Cboe 250 was down 1.4% at 15,118.68, and the Cboe Small Companies down 0.3% at 9,598.65.

Stocks in mainland Europe weren't faring much better. The CAC 40 index in Paris was down 2.1%, while the DAX 30 in Frankfurt was down 1.4%

"China was first in to the coronavirus crisis and arguably one of the first to come out of its first phase, so the fragile nature of its recovery offers an uncomfortable view of the future for other countries," said AJ Bell investment director Russ Mould.

Retail sales – a key indication of consumer sentiment – shrank by 1.1% on-year in July, falling short of forecasts and suggesting many are still reticent about going out to spend time and money, even as China appears to have the virus largely under control. The latest data follows a drop of 1.8% on-year for retail sales in June.

Meanwhile, industrial production in China grew by 4.8% in July, the same as the previous month, but below predictions of 5.2% growth.

In London, International Consolidated Airlines Group was down 5.5%. Shares in the British Airways parent were lower after the UK added France to its 14-day quarantine list.

People arriving in the UK after 0400 BST on Saturday will be required to spend 14 days in self-isolation due to rising numbers of coronavirus cases in France. The conditions also will apply to travellers returning to the UK from the Netherlands, Monaco, Malta, Turks & Caicos and Aruba.

The move, which applies throughout the UK, comes after Prime Minister Boris Johnson promised to be "absolutely ruthless" in decisions about imposing quarantine restrictions on countries.

The problem for airlines is that people's desire for a break in the sun may be outweighed by their fear of the logistical challenges of holing up for two weeks when they get back home, with decisions on which countries to add to the quarantine list often coming at short notice.

"With France being added to the quarantine list for the UK, travel & leisure is under pressure. Shares in IAG, Ryanair, Tui and EasyJet were all sharply lower as the move will force a large swathe of cancellations right at the peak of the summer holiday season for one of the largest markets for UK tourists. Half a million Brits are thought to be in France right now," noted Markets.com analyst Neil Wilson.

Irish budget carrier Ryanair Holdings was down 4.6%. UK peer easyJet was down 6.5%. Dart Group, which owns the Jet2 airline, was down 7.1%.

Anglo-German holiday operator TUI was down 5.3%.

Outside of travel stocks, Rank Group was the best mid-cap performer, up 2.4%, ahead of UK casinos being allowed to reopen on Saturday.

Casinos, bowling alleys and casinos were on the list of UK businesses that will be allowed to welcome customers back for the first time on Saturday after months of lockdown.

Hollywood Bowl Group was up 8.5%, while Ten Entertainment Group was up 3.2%.

At the other end of the FTSE 250 index, WH Smith was down 3.7%. The books and stationery retailer makes a substantial amount of its revenue from stores in airports and train stations and so also is threatened by travel restrictions.

On the AIM, Verona Pharma was up 21%. The drugmaker said the impact of Covid-19 on clinical trials in the first half has been limited.

Verona remains on track to start its Phase 3 clinical trials with ensifentrine for the treatment of chronic obstructive pulmonary disease later in 2020. It also has received a notice from US Food & Drug Administration to proceed with a study of ensifentrine in patients with Covid-19 at the University of Alabama.

In New York, the Dow Jones Industrial Average was pointed to open down 0.5%, the S&P 500 index down 0.3% and the Nasdaq Composite down 0.1%.

The pound was quoted at USD1.3094 on Friday at midday, firm from USD1.3084 at London equities close Thursday.

The euro was priced at USD1.1807, down from USD1.1830. Against the yen, the dollar was quoted at JPY106.75 in London, lower from JPY106.90.

The eurozone economy crashed 12% in the second quarter of 2020, according to figures from Eurostat on Friday.

This quarter-on-quarter decline was the worst reading since the series started in 1995. In the first three months of the year, gross domestic product fell 3.6% sequentially.

Year-on-year, the eurozone economy shrank 15% in the three months to June, again the sharpest decline seen since 1995 and a deterioration from the 3.1% fall posted for the first quarter. Two quarters in a row of contraction mean the eurozone economy has entered into recession.

In commodities, Brent oil was trading at USD44.66 a barrel Friday midday, down from USD45.18 a barrel Thursday evening in London.

Gold was quoted at USD1,950.86 an ounce at midday, slightly higher from USD1,947.60 an ounce at the London equities close Thursday.

Still to come in the economic events calendar on Friday are US retail sales figures at 1330 BST.

By Neetika Kurup; neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
7 Mar 2014 09:39

Friday broker round-up UPDATE

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re

Read more
6 Mar 2014 18:02

Verona Pharma Looks To Raise Up To GBP14 Million In Share Placing

LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t

Read more
11 Nov 2013 08:50

Monday broker round-up UPDATE

Associated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin

Read more
25 Oct 2013 08:35

Verona Pharma Says RPL554 Drug Trial Positive

Read more
30 Sep 2013 12:47

Verona Pharma Widens Losses As Treatment Development Continues

Read more
5 Sep 2013 09:37

Verona Pharma Appoints Chroma CEO Bungay As New Part-Time CFO

Read more
5 Sep 2013 08:15

Verona Pharma replaces CFO Lowe with Bungay

Verona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.

Read more
23 Jul 2013 16:21

SABMilller Chairman sells over 11m pounds in shares

Graham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so

Read more
26 Apr 2013 15:09

Advanced Oncotherapy CEO makes triple purchase

The Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p

Read more
10 Apr 2013 16:27

AZ Electronic Materials directors try to minimize damage

John Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta

Read more
4 Sep 2012 08:58

Small caps round-up: Verona, Image Scan, Avia

Respiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra

Read more
28 Aug 2012 14:43

Small caps round-up: Transense Tech, Hightex, Verona Pharma

Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones

Read more
9 Jul 2012 10:25

Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.

Read more
26 Nov 2010 15:56

Small caps round-up: Verona Pharma, PHSC, Sterling Green

Verona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi

Read more
28 Jun 2010 07:33

Verona Pharma In Talks With Licensees For RPL554 Cough Project

LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.